CAR-T Cell Therapy
Hematology
Starting from
$47,000
Up to $200,000 depending on centre
Typical duration
20–50 days
Including pre-operative work-up
Partner hospitals
0
Vetted for outcome data & accreditation
Overview
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary form of personalised cancer immunotherapy in which a patient's own T-cells are genetically engineered to identify and destroy cancer cells with precision. Approved for certain blood cancers — including relapsed or refractory B-cell lymphomas, acute lymphoblastic leukaemia (ALL), and multiple myeloma — CAR-T has achieved remission in patients who failed all prior therapies. China is a world leader in CAR-T innovation with domestically approved products (Relma-cel, Yescarta/Fosun Kite) at a fraction of US costs. India offers the homegrown NexCAR19 product at around $50,000 — one-tenth of the US price — through JCI-accredited centres including Christian Medical College Vellore.
Your case is matched to a centre on the basis of clinical outcome data, not marketing. We coordinate every step — from pre-operative work-up to post-treatment follow-up — with a dedicated care coordinator.
What's included
CAR-T Cell Therapy
Coordinated from
or message us on WhatsApp
No commitment required. Your data is never shared with third parties.
Global cost comparison — CAR-T Cell Therapy
Average coordinated costs across our partner centres. Final pricing depends on clinical complexity and chosen hospital.
| Country | Avg. cost | vs. cheapest |
|---|---|---|
🇮🇳 India New Delhi · Chennai · Bengaluru · Hyderabad · Mumbai · Kochi | $65,000 | —chevron_right |
🇨🇳 China Shanghai · Beijing · Hainan (Boao) | $150,000 | +131%chevron_right |
Costs are indicative and reviewed quarterly. Request a personalised estimate for your specific case.
Frequently asked questions
CAR-T is currently approved for relapsed or refractory large B-cell lymphoma (including DLBCL), follicular lymphoma, mantle cell lymphoma, B-cell acute lymphoblastic leukaemia (ALL), and multiple myeloma after prior lines of therapy. Eligibility depends on your specific cancer subtype, prior treatment history, molecular markers (e.g., CD19, BCMA expression), and performance status. Our partner centres will review your pathology reports, treatment history, and imaging to determine candidacy before you travel.
No fees. No commitment.
Our guidance is completely free
We are compensated by our partner hospitals — never by patients. You get independent clinical matching, cost transparency, and end-to-end coordination at no cost to you.